JPRN-jRCT2080223391
Completed
Phase 1
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
ConditionsAdvanced Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Advanced Solid Tumors
- Sponsor
- AstraZeneca
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have histologic documentation of advanced solid tumors
- •\- Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option
Exclusion Criteria
- •\- Concurrent enrollment in another clinical study
- •\- Prior participation in clinical studies that include durvalumab alone or in combination
- •\- Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A study to evaluate the safety of panitumumab and children with solid tumoursEUCTR2014-005190-36-Outside-EU/EEAAmgen Inc36
Completed
Not Applicable
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects with Glioblastoma MultiformeGlioblastomaGrade 4 Brain tumor10029211NL-OMON41552AbbVie B.V.10
Not yet recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000808549Bluejay Therapeutics, Inc40
Not yet recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000809538Bluejay Therapeutics, Inc80
Unknown
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients with Advanced or Refractory Solid Tumors or LymphomaJPRN-jRCT2080223021Janssen Pharmaceutical K.K.33